However, in a retrospective analysis that included 168 KRAS G12C and 219 KRAS non-G12C patients with advanced NSCLC treated with ICIs, ORR, PFS, and OS were better in patients with KRAS G12C mutations. Here, KRAS is linked to non-small cell lung carcinoma.